Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325273 | 0.92 | PTPN5 (0.58) | TRPM8PTPN5MAPTGABRA1GABRG2 | |
| SCHEMBL6318627 | 0.91 | PTPN5 (0.50) | TRPM8PTPN5MAPTHPGDALDH1A1 | |
| SCHEMBL6325133 | 0.88 | POLB (0.49) | PTPN5MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL5882131 | 0.87 | PTPN5 (0.64) | TRPM8PTPN5MAPTGABRA1GABRG2 | |
| SCHEMBL5881928 | 0.84 | MEN1 (0.50) | PTPN5MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL6318392 | 0.84 | MCL1 (0.49) | TRPM8PTPN5 | |
| SCHEMBL5882184 | 0.83 | PDE3B (0.56) | PTPN5MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL5881887 | 0.82 | KDM4E (0.50) | PTPN5MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL6319864 | 0.82 | PTPN5 (0.58) | TRPM8PTPN5HPGDALDH1A1KDM4E | |
| SCHEMBL6327244 | 0.81 | PTPN5 (0.45) | PTPN5MAPTHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| CN-1150167-C | Indole derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| CN-1303371-A | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-11 | — | — | CN | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | TRPM8 3042/4885PTPN5 108/4885MAPT 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.